Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Collegium Pharmaceutical Inc (NASDAQ: COLL) closed at $35.75 down -1.13% from its previous closing price of $36.16. In other words, the price has decreased by -$1.13 from its previous closing price. On the day, 0.76 million shares were traded. COLL stock price reached its highest trading level at $36.25 during the session, while it also had its lowest trading level at $35.47.
Ratios:
For a deeper understanding of Collegium Pharmaceutical Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.58. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.18. In the meantime, Its Debt-to-Equity ratio is 4.10 whereas as Long-Term Debt/Eq ratio is at 3.81.
On July 30, 2024, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $47.
Jefferies Upgraded its Hold to Buy on June 07, 2024, whereas the target price for the stock was revised from $41 to $44.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 29 ’25 when Smith Thomas B sold 17,478 shares for $38.42 per share. The transaction valued at 671,576 led to the insider holds 70,264 shares of the business.
Smith Thomas B bought 17,478 shares of COLL for $671,576 on Aug 29 ’25. On Aug 18 ’25, another insider, Dreyer Scott, who serves as the EVP & Chief Commercial Officer of the company, sold 16,389 shares for $38.21 each. As a result, the insider received 626,171 and left with 103,613 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, COLL now has a Market Capitalization of 1126201088 and an Enterprise Value of 1855785088. As of this moment, Collegium’s Price-to-Earnings (P/E) ratio for their current fiscal year is 34.51, and their Forward P/E ratio for the next fiscal year is 4.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.59 while its Price-to-Book (P/B) ratio in mrq is 4.86. Its current Enterprise Value per Revenue stands at 2.625 whereas that against EBITDA is 4.939.
Stock Price History:
The Beta on a monthly basis for COLL is 0.66, which has changed by -0.06438106 over the last 52 weeks, in comparison to a change of 0.1653893 over the same period for the S&P500. Over the past 52 weeks, COLL has reached a high of $42.29, while it has fallen to a 52-week low of $23.23. The 50-Day Moving Average of the stock is 1.48%, while the 200-Day Moving Average is calculated to be 15.09%.
Shares Statistics:
For the past three months, COLL has traded an average of 378.94K shares per day and 512660 over the past ten days. A total of 31.55M shares are outstanding, with a floating share count of 30.50M. Insiders hold about 3.18% of the company’s shares, while institutions hold 115.64% stake in the company. Shares short for COLL as of 1756425600 were 4324706 with a Short Ratio of 11.41, compared to 1753920000 on 4215754. Therefore, it implies a Short% of Shares Outstanding of 4324706 and a Short% of Float of 16.450001.
Earnings Estimates
The company has 5.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $2.24, with high estimates of $2.66 and low estimates of $2.0.
Analysts are recommending an EPS of between $10.47 and $6.91 for the fiscal current year, implying an average EPS of $7.79. EPS for the following year is $8.34, with 5.0 analysts recommending between $10.76 and $6.65.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $191.25M this quarter.It ranges from a high estimate of $194.14M to a low estimate of $189.6M. As of. The current estimate, Collegium Pharmaceutical Inc’s year-ago sales were $159.3MFor the next quarter, 5 analysts are estimating revenue of $199.71M. There is a high estimate of $215.8M for the next quarter, whereas the lowest estimate is $187.7M.
A total of 5 analysts have provided revenue estimates for COLL’s current fiscal year. The highest revenue estimate was $773.36M, while the lowest revenue estimate was $743M, resulting in an average revenue estimate of $756.69M. In the same quarter a year ago, actual revenue was $631.45MBased on 5 analysts’ estimates, the company’s revenue will be $777.76M in the next fiscal year. The high estimate is $789.7M and the low estimate is $751.5M.
